GHK-Cu Reconstitution Calculator

No. GHK-Cu is not FDA-approved as a drug for any indication; as an injectable it falls in the unapproved "gray market" class. The best human data are two small aesthetic RCTs showing reduced wrinkle volume/depth and improved post-laser patient satisfaction. A 13-participant post-CO2-laser RCT was negative on objective endpoints, and an 18-participant split-face eyebrow study was positive for hair outcomes but undefined on copper speciation. A phase 2 acute-wound trial (NCT07437586) is recruiting without efficacy data.

Topical GHK-Cu is hydrophilic and poorly penetrates the stratum corneum,; microneedles and ~100 nm liposomes (encapsulation ~20-32%) improve dermal delivery. In aged mice, intraperitoneal dosing produced transient, male-only cognitive improvement, while intranasal 15 mg/kg over 8 weeks improved cognition in both sexes via distinct molecular programs (animal). Intra-articular 0.3-3 mg/ml transiently improved rat ACL graft healing (animal). Subcutaneous injection is the standard community route for systemic skin/ECM effects (community protocol).

No human dose-response data exist; indications, dosing, frequency, and duration remain unknown clinically. Preclinical anchors: intraperitoneal 0.2-2 mg/kg reversed cigarette-smoke-induced muscle dysfunction in mice (animal); collagen synthesis in fibroblasts peaks at 10⁻⁹ M (in-vitro). Plasma GHK declines from ~200 ng/ml at age 20 to ~80 ng/ml by age 60, framing supplementation as restoration rather than excess. Community protocols typically use subcutaneous 1–2 mg commonly reported, with community protocols of daily or 3–4×/week for 4–6 weeks; cosmetic mesotherapy 1–5 mg (community protocol).

Short-term preclinical safety is favorable: no significant systemic toxicity in a silicosis mouse model, but rigorous human safety data are scarce. No pregnancy or lactation data exist in the literature. GHK-Cu functions as a copper-delivery system, and speciation plus labile copper content vary between products. Practitioners commonly avoid it in Wilson's disease, known copper intolerance, or elevated ceruloplasmin, and keep doses in the low-mg range to limit copper load (practitioner consensus).

Controlled preclinical exposures have run 8 weeks intranasally. GHK-Cu is unstable in biological fluids, favoring frequent dosing or stabilized nanoparticle/liposome formulations. Community practice: 4-6 week cycles with ≥4-week breaks; no long-term human data justify continuous use (community protocol).

All three are unapproved peptides with largely preclinical evidence,. The divergence is mechanistic: GHK-Cu's core data are dermal extracellular matrix: collagen, elastin, glycosaminoglycan synthesis, and MMP/TIMP modulation; BPC-157's are tendon and gut repair; TB-4/TB-500's are blood vessel growth (angiogenesis). Select GHK-Cu for skin quality and anti-aging goals; BPC-157 or TB-500 for musculoskeletal goals, though none has human orthopaedic efficacy data.

Lyophilized powder: refrigerate and protect from light (community protocol). Reconstituted GHK-Cu degrades in solution, with copper dissociation and oxidation observed across formulations,; community practice is refrigerated use within ~30 days, discarding on color change or precipitation (community protocol). Because injectable GHK-Cu is unapproved, international travel with vials carries legal risk; domestic transport of labeled lyophilized vials is common community practice (community protocol).